After a comprehensive filtering based on multiple resources including a PheWAS analysis and interrogation of Human Phenotype Ontology as well as SIDER databases, potential vascular drug targets such as MAP3K11, CAMK1D, PDGFD, IPO9 and CETP were not predicted to be associated with major adverse side effects (cardiovascular, neurologic, metabolic, cancer) that would result from drug inhibition. This evidence concerns the gene PDGFD and cancer.